Mumbai, August 11 (Udaipur Kiran): Zydus Lifesciences is currently trading at Rs. 1115.35 and has touched a high and low of Rs. 1181.00 on 08-Jul-2026 and a 52 week low of Rs. Zydus Lifesciences has launched REVAHALE (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). REVAHALE has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow.